Screener
Beta Bionics BBNX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
FAQ
- What is Beta Bionics's cash & equivalents?
- Beta Bionics (BBNX) reported cash & equivalents of $44.32M in Q2 2026.
- How has Beta Bionics's cash & equivalents changed year-over-year?
- Beta Bionics's cash & equivalents increased by 26.4% year-over-year, from $35.08M to $44.32M.
- What is the long-term trend for Beta Bionics's cash & equivalents?
- Over 2 years (2023 to 2025), Beta Bionics's cash & equivalents has grown at a 9.0% compound annual growth rate (CAGR), from $26.57M to $31.58M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Beta Bionics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude